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Despite intensive efforts to improve tuberculosis (TB) care
and control, the global burden of TB is falling only slowly, and
the evolution of drug resistance remains uncertain. According
to the WHO, the estimated incidence in 2009 was 9.4 million
new cases [1]. In recent years, TB treatment has become
more complicated because of the emergence of multidrug-
resistant (MDR) TB, i.e. TB caused by strains resistant to iso-
niazid and rifampin. In 2009, an estimated 250 000 patients
had MDR TB, representing 3.3% of new TB cases and up to
28% in certain countries of the former Soviet Union [1]. In
2008, the number of deaths caused by MDR TB was
estimated to be 150 000. The emergence of extensively drug-
resistant (XDR) TB, deﬁned by resistance to isoniazid and
rifampin combined with additional resistance to a
ﬂuoroquinolone and at least 1 s line injectable agent (amika-
cin, kanamycin, or capreomycin), has been associated with
increasing mortality (65–100%), as efﬁcient therapy is not
available [2]. By July 2010, 58 countries had reported at least
one case of XDR TB [1]. These alarming data highlight the
urgent need for new anti-TB drugs. Except for ﬂuroquinol-
ones, no novel anti-TB antibiotic has been introduced in the
last 45 years.
b-Lactams have not been considered to be useful drugs
for the treatment of TB, because Mycobacterium tuberculosis
naturally produces BlaC, an extended-spectrum class A b-lac-
tamase [3]. However, older reports have shown that the
combination of amoxycillin and clavulanic acid is bactericidal
in vitro [4], an efﬁcacy that can be accounted for by the
recent demonstration that BlaC is irreversibly inactivated by
clavulanic acid [3]. Reduction of the burden of M. tuberculosis
in the sputum of patients treated with amoxycillin and clavul-
anic acid has been reported [5], but clinical assessments for
the treatment of MDR TB are limited to anecdotal cases in
which amoxycillin–clavulanic acid was used in association
with second-line drugs [6].
Among the different classes of b-lactams, very recent data
concerning carbapenems have opened new avenues towards
the potential use of this class in the treatment of TB, espe-
cially for MDR and XDR TB. Until recently, all b-lactams
were thought to exclusively act on the active-site serine
D,D-transpeptidases, the classic penicillin-binding proteins that
catalyse the ﬁnal cross-linking step of peptidoglycan synthesis.
We have recently shown that these D,D-transpeptidases are
bypassed by a novel family of polymerases, the active-site
cysteine L,D-transpeptidases (Ldts), in b-lactam-resistant
enterococci and in M. tuberculosis [7,8]. These enzymes are
promising targets for the use of carbapenems, or for the
development of anti-TB drugs belonging to this class, because
the Ltds are responsible for the formation of 80% of the
cross-links in M. tuberculosis, and these enzymes are irrevers-
ibly inactivated by carbapenems by the formation of covalent
adducts [8,9]. Moreover, one of the ﬁve Ltds of M. tuberculo-
sis (LdtMt2) is essential for virulence in a mouse model of
acute infection [9]. Carbapenems are slowly hydrolysed by
the b-lactamase BlaC [3], and one member of the carbape-
nem family, meropenem, has been reported to be uniformly
active in vitro in association with clavulanic acid against a
panel of XDR strains (meropenem MIC of <1 mg/L in the
presence of 2.5 mg/L clavulanic acid [10]. Carbapenems may
also have potential applications for the treatment of suscepti-
ble TB, because meropenem–clavulanic acid is active against
non-replicative forms (‘dormant’ forms) of M. tuberculosis
[10], which are difﬁcult to eradicate even with isoniazid and
rifampin. The adaptive response of M. tuberculosis during the
transition from aerobic growth to stationary phase results in
the activation of a ‘dormancy’ regulon, which includes genes
that are likely to play an essential role in the long-term sur-
vival of the bacteria, and therefore encode potential targets
for the development of sterilizing drugs. Among these genes,
Rv0116c, which encodes LdtMt1, is upregulated 17-fold [11].
Thus, LdtMt1 could be an essential target accounting for the
bactericidal activity of meropenem–clavulanic acid against
dormant forms of M. tuberculosis in vitro [10]. In a mouse
model, imipenem alone had antimycobacterial activity,
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although this carbapenem was less effective than isoniazid
[12]. More recently, imipenem or meropenem associated
with clavulanic acid was shown to improve the survival of
mice infected with M. tuberculosis, although the combinations
were less effective than isoniazid alone [13]. To date, the
clinical experience with carbapenems is positive but very lim-
ited, and the b-lactams have only been used in combination
with ﬁrst-line and second-line drugs [12].
Despite very encouraging in vitro data highlighting carba-
penems as promising agents for the treatment of resistant
TB, there are several limitations, including the intravenous
route of administration of all approved carbapenems (except
for faropenem in Japan), the risks inherent in long-term vas-
cular access, high costs, and very limited clinical experience.
However, in vitro efﬁcacy and the evolution of resistance jus-
tify the design of clinical studies to assess the efﬁcacy of car-
bapenems in association with clavulanic acid in the treatment
of MDR and XDR TB. The development of carbapenem-
related compounds may also lead to drugs that are not
hydrolysed by BlaC and are appropriate for TB treatment.
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